



DIABETES MELLITUS: A COMPREHENSIVE REVIEW OF PATHOPHYSIOLOGY, EPIDEMIOLOGY, CLINICAL MANAGEMENT, AND FUTURE DIRECTIONS

Pharmacy Practice

Dr. Subhranshu Panda	Director, School Of Pharmaceutical Sciences, Jaipur National University Jaipur, Rajasthan, 302017
Mr. Pintu Kumar*	Doctor Of Pharmacy, School Of Pharmaceutical Sciences, Jaipur National University Jaipur, Rajasthan, 302017*Corresponding Author
Mr. Aditya Rao	Doctor Of Pharmacy, School Of Pharmaceutical Sciences, Jaipur National University Jaipur, Rajasthan, 302017
Mr. Dishank Yadav	Doctor Of Pharmacy, School Of Pharmaceutical Sciences, Jaipur National University Jaipur, Rajasthan, 302017
Mr. Vanish Chande	Doctor Of Pharmacy, School Of Pharmaceutical Sciences, Jaipur National University Jaipur, Rajasthan, 302017
Mr. Abdul Rehman	Doctor Of Pharmacy, School Of Pharmaceutical Sciences, Jaipur National University Jaipur, Rajasthan, 302017

ABSTRACT

Diabetes, also called type 2 diabetes, is a big medical issue around the world, affects thousands of millions of people. The number of people who get it is rising each year, especially in low- and middle-income nations. This review examines how diabetes has grown and spread worldwide, focusing on the main causes of Diabetes with type 1 with type 2 (T1D) and T2D): autoimmune destruction of pancreatic beta cells and insulin resistance, respectively. This study examines how management approaches, such as lifestyle changes, medication, and new technologies, affect health outcomes. The text also discusses how more people are being diagnosed with diabetes, how to identify it, current treatments, personalised treatment plans, and how public health policy can help prevent and manage the disease. The goal is to make diabetes easier to understand and stress the need for more research and better treatment.

KEYWORDS

diabetes mellitus, pathophysiology, epidemiology, clinical management, future directions, insulin resistance, β -cell dysfunction

INTRODUCTION

Diabetes is a long-term health issue where blood sugar gets too high. As per 2021 data, approximately 537 million adults are living with diabetes globally, and this figure is projected to increase to 783 million by 2045 [1], which shows a significant rise in prevalence. Figuring out why it happens, what makes it more likely, and how to deal with it. for diabetes is important as the number of affected individuals continues to grow worldwide.

Type 1 diabetes (T1D) and type 2 diabetes (T2D) are the most prevalent forms of diabetes, with T1D being an autoimmune disorder that leads to the destruction of pancreatic beta cells and results in complete insulin deficiency [2]. T2D accounts for nearly 90–95% of all diabetes cases and is mainly associated with insulin resistance and inadequate insulin secretion, which is often related to obesity and lifestyle factors [3]. Other types include gestational diabetes mellitus (GDM), diabetes due to specific genetic mutations, and cases arising from pancreatic diseases or the use of certain medications [4].

This review discusses the development and prevalence of diabetes, current approaches to management, and future directions for research. The main goal is to provide doctors and nurses, researchers, and policymakers with a comprehensive summary of recent findings and to highlight the most important areas that require further research and action.

PATHOPHYSIOLOGY

TYPE 1 DIABETES (T1D)

Type 1 diabetes is the thing that makes it hard for people to control the amount of sugar in their blood. The immune system's targeted destruction of pancreatic β -cells leads to total insulin deficiency [2]. The pathogenesis entails a multifaceted interaction between genetic predisposition and environmental factors. The human leukocyte antigen (HLA) region, particularly HLA-DR3 and HLA-DR4, is a significant genetic locus associated with an elevated risk [5]. Environmental factors, including viral infections (e.g., enteroviruses), dietary influences, and early-life exposures, are believed to initiate or accelerate β -cell autoimmunity [6].

The autoimmune process is marked by the presence of autoantibodies

targeting β -cell antigens, such as insulin, the enzyme glutamic acid decarboxylase (GAD65), islet antigen 2 (IA-2), and the zinc transporter 8 (ZnT8) [7]. These antibodies can be detected years before the disease starts, making it easier to identify people at risk. The gradual destruction of β -cells causes insulin secretion to be less effective, which leads to high blood sugar levels and the typical signs of diabetes, such as experiencing excessive thirst, frequent urination, and weight loss [2].

TYPE 2 DIABETES (T2D)

Diabetes type 2 is a diverse condition influenced by the interaction of environmental, genetic, and behavioural factors. The main problems are insulin resistance in peripheral tissues (especially muscle, liver, and adipose tissue) and β -cell dysfunction that worsens over time [8]. Insulin resistance often precedes hyperglycemia. For many years, β -cells initially compensated by secreting more insulin. But over time, β -cell failure occurs, leading to diabetes [9].

Insulin resistance is caused by several pathophysiological mechanisms, including ectopic lipid accumulation, swelling, mitochondrial dysfunction, and endoplasmic reticulum stress [10]. Inflammation of adipose tissue, characterised by macrophage infiltration and cytokine release, is a major cause of systemic insulin resistance [11]. When the liver becomes insulin-resistant, it produces more glucose, which elevates fasting blood sugar levels [12]. Figure 1:




Figure 1:

In T2D, β -cells don't function properly, meaning they don't release insulin properly, die more often, and lose their specialised functions [13]. Genetic factors affect the function and mass of β -cells. More than

Sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists are all second-line treatments [44]. Choosing an agent must be based on its effectiveness, the risk of hypoglycemia, its effect on weight, cardiovascular outcomes, kidney function, cost, and the patient's preferences [45].

SGLT2 inhibitors and GLP-1 receptor agonists are preferred treatments for people with atherosclerotic cardiovascular disease (CVD) or chronic kidney disease (CKD) because they benefit both the heart and the kidneys [46]. SGLT2 inhibitors lower the risk of heart problems and hospitalisations for heart failure, and they also slow the progression of diabetic kidney disease [47]. GLP-1 receptor agonists help people lose weight and lower the risk of major adverse cardiovascular events (MACE) [48].

MONITORING AND GLYCEMIC TARGETS

People with diabetes may monitor their blood sugar levels through self-monitoring of blood glucose (SMBG), continuous glucose monitoring (CGM), and checking their long-term glycaemic control with HbA1c [49]. CGM systems provide real-time glucose data, patterns, and alerts that help you better control your blood sugar and lower your risk of hypoglycemia, especially if you have T1D [50].

The normal goal for most adults who aren't pregnant is an HbA1c level below 7% (53 mmol/mol). Some people may need stricter targets (below 6.5% or 48 mmol/mol), while others with many other health problems should aim for less strict targets (below 8% or 64 mmol/mol) [4]. It is very important to lower the risk of heart disease, which includes controlling blood pressure (for most patients, the goal is less than 130/80 mmHg), managing lipids (for patients at least 40 years old, statin therapy is recommended), and taking antiplatelet therapy (also known as aspirin for secondary prevention) [51]. For people with diabetes who have high blood pressure, renin-angiotensin-aldosterone system (RAAS) inhibitors are better [52].

FUTURE DIRECTIONS EMERGING THERAPIES

Research into new ways to treat diabetes continues. In type 1 diabetes (T1D), researchers are investigating immunomodulatory agents such as anti-CD3 (teplizumab) and anti-CD20 (rituximab) antibodies to preserve β -cell function. Teplizumab was recently approved by the FDA to delay the onset of clinical Type 1 Diabetes in people who are at risk [53]. Islet cell transplantation and stem cell-derived β -cells are two types of β -cell replacement therapies that could help people live without insulin [54].

In individuals with type 2 diabetes (T2D), dual and triple incretin agonists, including the tripeptide (a GIP/GLP-1 receptor agonist), have shown enhanced glycaemic control and weight reduction compared with single incretin therapies [55]. New drugs targeting other pathways, such as glucagon receptor antagonists, free fatty acid receptor agonists, and mitochondrial uncouplers, are currently under development [56].

PRECISION MEDICINE

Precision medicine seeks to customise diabetes prevention and treatment based on each person's unique genetic, phenotypic, and environmental traits. Genetic risk scores can pinpoint individuals at elevated risk for T2D, facilitating targeted preventive measures [57]. Grouping patients with diabetes by genetic and clinical information could help personalize treatment [58]. Pharmacogenetics can predict responses to drugs such as sulfonylureas and GLP-1 receptor agonists, but it's not widely used in clinical practice yet [59].

TECHNOLOGY AND DIGITAL HEALTH

New technologies for diabetes, such as CGM, insulin pumps, and closed-loop systems (an artificial pancreas), are changing how diabetes is managed. Closed-loop systems that continually adjust insulin dosing based on continuous glucose monitor readings have shown better glycaemic control and fewer hypoglycemic episodes in both type 1 and type 2 diabetes [60].

Digital health methods such as mobile apps, telemedicine, and coaching sites help people manage their own health and access care, especially those who don't have good access [61]. Researchers are working on algorithms using machine learning and AI that can find patients who are at risk of complications, figure out the best insulin dose, and predict glycaemic excursions [62].

5.4 PREVENTION STRATEGIES

The Program for Diabetes Prevention and the Finnish Insulin Prevention Research Project are two examples of randomised controlled trials that have shown that lifestyle changes can help prevent T2D. These 5–7% through diet and exercise can lower the risk of diabetes by about 58% in people who are already at risk [63]. To turn these results into strategies for the whole population, we need to examine food systems, physical activity settings, and the socioeconomic factors that affect health [64].

Fiscal measures such as taxes on sugary drinks, front-of-pack labelling, restrictions on marketing unhealthy foods to kids, and urban planning that encourages active lifestyles are examples of population-based prevention strategies [65]. In the United States, the National Diabetes Prevention Program (NDPP) and other community-based programs have been established to help at-risk individuals follow structured lifestyle plans [66].

SPECIAL POPULATIONS PEDIATRIC DIABETES

Type 1 diabetes (T1D) is the most common type of diabetes in children and teens, but type 2 diabetes (T2D) is becoming more common, especially in the context of childhood obesity [67]. Managing diabetes in children requires care that is appropriate for their age, such as insulin therapy, nutritional counselling, and psychosocial support [68]. The shift from paediatric to adult diabetes care is a critical period associated with deteriorating glycaemic control and an increased risk of complications [69].

GESTATIONAL DIABETES

Gestational diabetes mellitus (GDM) affects about 14% of pregnancies worldwide, and this number is going up because more women are becoming obese [70]. Screening and diagnosis usually occur between 24 and 28 weeks of pregnancy with a 75-g OGTT [4]. Management encompasses medical nutrition therapy, exercise, and insulin therapy, with oral drugs (metformin, glyburide) deemed acceptable in certain contexts [71]. After giving birth, follow-up is important to assess the mother's glucose metabolism and provide guidance on planning for future pregnancies and avoiding diabetes [72].

DIABETES IN OLDER ADULTS

More and more older adults with diabetes are having trouble managing their condition because they are more likely to have low blood sugar, take multiple medications, experience cognitive decline, and have trouble doing everyday tasks [73]. Glycaemic goals should be different for each person. For people with a short life expectancy or many other health problems, the goals should be less strict (e.g., HbA1c < 8.0% or 64 mmol/mol) [4]. Even though blood pressure goals may not be as strict for frail people, it is still important to control cardiovascular risk factors, such as high blood pressure and dyslipidemia [74].

CONCLUSION

Diabetes mellitus continues to be a significant global health issue, impacting hundreds of millions of people and placing a considerable burden on individuals, families, and healthcare systems. This review has discussed the main causes of diabetes, such as autoimmune disorders and beta-cell destruction in type 1 diabetes, and the relationship between insulin resistance and beta-cell dysfunction in type 2 diabetes. The increasing prevalence of diabetes is closely linked to rising obesity rates and reduced physical activity, with the most rapid growth expected in low- and middle-income countries. Advances in medicines, technologies, and healthcare delivery have improved diabetes management. Lifestyle modification remains the most important part of treatment, while newer drugs like SGLT2 inhibitors and GLP-1 receptor agonists provide additional benefits for blood sugar control and protection of the heart and kidneys. Technologies including closed-loop systems, continuous glucose monitoring, and digital health tools are also transforming diabetes care. However, ensuring equal access to care for all remains a challenge. Addressing the diabetes epidemic requires strategies focused on prevention, early detection, and improved access to quality healthcare. Reducing the global impact of diabetes will need coordinated efforts from healthcare professionals, researchers, policymakers, and communities.

ACKNOWLEDGEMENT

I would like to express my heartfelt thanks to my parents and all the

faculty members for their invaluable help and support in the publication of this review article.

CONFLICT OF INTEREST: None

Abbreviations

DM – Diabetes Mellitus
 T1DM – Type 1 Diabetes Mellitus
 T2DM – Type 2 Diabetes Mellitus
 GDM – Gestational Diabetes Mellitus
 NCDs - Non-Communicable Diseases
 SMBG – Self-Monitoring of Blood Glucose
 DASH - Dietary Approaches to Stop Hypertension
 CGM - Continuous Glucose Monitoring

REFERENCES

- International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2021
- Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. *Lancet*. 2014;383(9911):69-82.
- DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes*. 2009;58(4):773-795.
- American Diabetes Association. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2023. *Diabetes Care*. 2023;46(Suppl 1):S19-S40.
- Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. *Lancet*. 2016;387(10035):2411-2420.
- Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. *Lancet*. 2016;387(10035):2340-2348.
- Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. *JAMA*. 2013;309(23):2473-2479.
- Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*. 2006;444(7121):840-846.
- Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *J Clin Invest*. 1999;104(6):787-794.
- Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. *J Clin Invest*. 2016;126(1):12-22.
- Hotamisligil GS. Inflammation and metabolic disorders. *Nature*. 2006;444(7121):860-867.
- Cook JR, Langlet F, Kode A, et al. Pathogenesis of selective insulin resistance in isolated hepatocytes. *J Biol Chem*. 2015;290(22):13972-13980.
- Marchetti P, Bugliani M, Boggi U, et al. The pancreatic beta cells in human type 2 diabetes. *Adv Exp Med Biol*. 2012;771:288-309.
- Flannick J, Florez JC. Type 2 diabetes: genetic data sharing to advance complex disease research. *Nat Rev Genet*. 2016;17(9):535-549.
- Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. *J Clin Invest*. 2006;116(7):1802-1812.
- NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet*. 2016;387(10027):1513-1530.
- WHO. Global Report on Diabetes. Geneva: World Health Organization; 2016.
- Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. *Lancet*. 2014;383(9911):69-82.
- DIAMOND Project Group. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. *Diabet Med*. 2006;23(8):857-866.
- Patterson CC, Dahlquist GG, Gyürüs E, et al. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-2020: a multicentre prospective registration study. *Lancet*. 2009;373(9680):2027-2033.
- Redondo MJ, Yu L, Hawa M, et al. Heterogeneity of type 1 diabetes: analysis of monozygotic twins in Great Britain and the United States. *Diabetologia*. 2001;44(3):354-362.
- Vehik K, Dabelea D. The increasing incidence of type 1 diabetes. *Lancet*. 2011;378(9786):41-42.
- Selvin E, Coresh J, Brancati FL. The burden and outcomes of hyperglycemia in older adults. *Diabetes Care*. 2006;29(8):1963-1964.
- Lammi N, Taskinen O, Moltchanova E, et al. A high incidence of type 1 diabetes and an alarming increase in incidence of type 2 diabetes among young adults in Finland. *Diabet Med*. 2007;24(8):830-836.
- Cheng YJ, Kanaya AM, Araneta MRG, et al. Prevalence of diabetes by race and ethnicity in the United States, 2011-2016. *JAMA*. 2019;322(24):2389-2398.
- Golden SH, Joseph JJ, Hill-Briggs F. Casting a health equity lens on endocrinology and diabetes. *J Clin Endocrinol Metab*. 2021;106(4):e1909-e1916.
- Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N Engl J Med*. 2011;364(9):829-841.
- Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. *Clin Exp Ophthalmol*. 2016;44(4):260-277.
- Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. *Diabetes Care*. 2014;37(10):2864-2883.
- Bommer C, Heeseemann E, Sagalova V, et al. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. *Lancet Diabetes Endocrinol*. 2017;5(6):423-430.
- Redondo MJ, Rewers M, Yu L, et al. Genetic determination of islet cell autoimmunity in monozygotic twin, dizygotic twin, and non-twin siblings of patients with type 1 diabetes: a prospective cohort study. *Lancet Diabetes Endocrinol*. 2014;2(2):134-140.
- Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. *Diabetes Care*. 2019;42(5):731-754.
- Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346(6):393-403.
- Franz MJ, Boucher JL, Rutten-Ramos S, VanWormeren JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. *J Acad Nutr Diet*. 2015;115(9):1447-1463.
- Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. *Diabetes Care*. 2016;39(11):2065-2079.
- Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. *JAMA*. 2011;305(17):1790-1799.
- Powers MA, Bardsley J, Cypress M, et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. *Diabetes Care*. 2015;38(7):1372-1382.
- American Diabetes Association. Insulin administration. *Diabetes Care*. 2004;27(Suppl 1):S106-S109.
- Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. *Diabetes Care*. 2005;28(4):950-955.
- Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2009;32(1):193-203.
- Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. *Diabetes Care*. 2006;29(10):2189-2195.
- Atkinson MA, Roep BO, Posgai A, et al. The challenge of modulating β -cell autoimmunity in type 1 diabetes. *Lancet Diabetes Endocrinol*. 2019;7(1):52-64.
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*. 1998;352(9131):854-865.
- American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2023. *Diabetes Care*. 2023;46(Suppl 1):S140-S157.
- Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2018;41(12):2669-2701.
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375(4):311-322.
- Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med*. 2016;375(4):309-317.
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375(19):1834-1844.
- American Diabetes Association. Glycemic targets: Standards of Medical Care in Diabetes—2023. *Diabetes Care*. 2023;46(Suppl 1):S97-S110.
- Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. *JAMA*. 2017;317(4):379-387.
- American Diabetes Association. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes—2023. *Diabetes Care*. 2023;46(Suppl 1):S158-S190.
- Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *Lancet*. 2000;355(9200):253-259.
- Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. *N Engl J Med*. 2019;381(7):603-613.
- Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. *N Engl J Med*. 2000;343(4):230-238.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. *N Engl J Med*. 2022;387(3):205-216.
- Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. *Lancet Diabetes Endocrinol*. 2021;9(8):525-544.
- Langenberg C, Lotta LA. Genomic insights into the causes of type 2 diabetes. *Lancet*. 2018;391(10138):2462-2474.
- Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol*. 2018;6(5):361-369.
- Pearson ER. Pharmacogenetics in diabetes. *Curr Diab Rep*. 2019;19(8):55.
- Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. *N Engl J Med*. 2019;381(18):1707-1717.
- Lee SWH, Ooi L, Lai YK. Telemedicine for the management of glycemic control and clinical outcomes of type 1 diabetes mellitus: a systematic review and meta-analysis of randomized controlled studies. *Front Pharmacol*. 2017;8:330.
- Woldaregay AZ, Årsand E, Walderhaug S, et al. Data-driven modeling and prediction of blood glucose dynamics: a systematic review of recent advances. *Inf Fusion*. 2017;38:117-130.
- Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*. 2001;344(18):1343-1350.
- Hawkes C, Smith TG, Jewell J, et al. Smart food policies for obesity prevention. *Lancet*. 2015;385(9985):2410-2421.
- World Health Organization. Report of the Commission on Ending Childhood Obesity. Geneva: World Health Organization; 2016.
- Albright AL, Gregg EW. Preventing type 2 diabetes in communities across the U.S.: the National Diabetes Prevention Program. *Am J Prev Med*. 2013;44(4 Suppl 4):S346-S351.
- Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. *J Pediatr*. 2005;146(5):693-700.
- American Diabetes Association. Children and adolescents: Standards of Medical Care in Diabetes—2023. *Diabetes Care*. 2023;46(Suppl 1):S230-S253.
- Peters A, Laffel L. Transitioning from pediatric to adult health care: a model for patients with type 1 or type 2 diabetes. *J Adolesc Health*. 2011;49(2 Suppl):S1-S2.
- International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels, Belgium: International Diabetes Federation; 2019.
- American Diabetes Association. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes—2023. *Diabetes Care*. 2023;46(Suppl 1):S254-S266.
- Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. *Diabetes Care*. 2002;25(10):1862-1868.
- American Diabetes Association. Older adults: Standards of Medical Care in Diabetes—2023. *Diabetes Care*. 2023;46(Suppl 1):S216-S229.
- Beckett NS, Peters R, Fletcher K, et al. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*. 2008;358(18):1887-1898.